New and emerging data from clinical trials of statins

Current Atherosclerosis Reports

Volumn 6, Issue 1, 2004, Pages 12-19

  LaRosa, John C ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; ATORVASTATIN; BEZAFIBRATE; CYANOCOBALAMIN; FENOFIBRATE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; FOLIC ACID; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RETINOL; SIMVASTATIN; TIROFIBAN; TRIACYLGLYCEROL; WARFARIN;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE REGIMEN; HEART DEATH; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; REVIEW; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 1842742309     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0111-9     Document Type: Review

References (34)

1. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
2. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22.
3. Athyros VG, Papageorgiou AA, Mercouris BR, et al.: Treatment with atorvastatin to the national cholesterol educational program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease-Evaluation (GREACE) Study. Curr Med Res Opin 2002, 18:220-228.
4. Shepherd J, Blauw GJ, Murphy MB, et al., on behalf of the PROSPER Study Group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623-1630.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
6. Sever PS, Dahlof B, Pouler NR, et al., for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensives patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003, 361:1149-1158.
7. Serruys PW, de Feyter P, Macaya C, et al., for the Lescol Intervention Prevention Study (LIPS) Investigators: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 2002, 287:3215-3222.
8. Holdaas H, Fellstrom B, Jardine AG, et al., on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 2003, 361:2024-2031.
9. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
10. LaRosa JC, Applegate W, Crouse JR III, et al.: Cholesterol Lowering in the Elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. Arch Intern Med 1994, 154:529-539.
11. LaRosa JC: Unresolved issues in early trials of cholesterol lowering. Am J Cardiol 1995, 76:5C-9C.
12. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997, 336:153-162.
13. Bloomfield Rubins H, Robins SJ, Collins D, et al., for the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
14. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21-27.
15. http://www.cardiosource.com/. Accessed on September 15, 2003.
16. Pederson TR, Kjekshus J, Pyorala K, et al.: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998, 81:333-335.
17. LaRosa JC, for the TNT Steering Committee: Effect of lowering LDL-C beyond currently recommended targets-the Treating to New Targets study. Presented at the XIIIth International Symposium on Drugs Affecting Lipid Metabolism. Florence, Italy, May 30 to June 3, 1998.
18. Pedersen TR, Faergeman O, Holme I, et al.: Effect of greater LDL-C reductions on prognosis - the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 1999, 144:38.
19. Isaacsohn JD, Davidson MH, Hunninghake D, et al.: Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) - rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol 2000, 86:250-251
20. MacMahon M, Kirkpatrick C, Cummings CE, et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000, 10:195-203.
21. Cannon CP, McCabe CH, Belder R, et al.: Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT) - TIMI 22 trial. Am J Cardiol 2002, 89:860-861.
22. Pitt B, Waters D, Brown WV, et al., for the Atorvastatin Versus Revascularization Treatment Investigators: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999, 341:70-76.
23. Schwartz GG, Oliver MF, Ezekowitz; MD, et al.: Rationale and design ofthe Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998, 81:578-581.
24. Ansell BJ: Cholesterol, stroke risk, and stroke prevention. Curr Atheroscler Rep 2000, 2:92-96.
25. Hebert PR, Gaziano M, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278:313-321.
26. The SPARCL Investigators: Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 2003, 16:389-395.
27. Meade TW, for the British Medical Research Council General Practice Research Framework and participating vascular clinics: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med 2001, 2:195-204.
28. Egan DB: Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 1999, 83:569-575.
29. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
30. Colhoun HM, Thomason MJ, Mackness MI, et al., and the CARDS Investigators: Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002, 19:201-211.
31. Gmerek A, McLain R, Nawrocki J: A 4-year placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin dependent diabetes mellitus. Diabetes 1997, 46(suppl 1):363A.
32. The PHYLLIS project group: Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensives subjects. J Hypertens 1993, 11(suppl 5):S314-S315.
33. Wanner C, KFane V, Ruf G, et al.: Rationale and design of a trial improving outcome of type 2 diabetics on haemolialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int 1999, 56(suppl 71):S222-S226.
34. Ulrich S, Hingorani AD, Martin J, Vallance P: What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ 2000, 320:1134-1140.